| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H22N4O2 |
| Molecular Weight | 350.4143 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCNC1=CC=C2N=CN3C2=C1C(=O)C4=C3C=CC(O)=C4
InChI
InChIKey=CUNDRHORZHFPLY-UHFFFAOYSA-N
InChI=1S/C20H22N4O2/c1-3-23(4-2)10-9-21-15-6-7-16-19-18(15)20(26)14-11-13(25)5-8-17(14)24(19)12-22-16/h5-8,11-12,21,25H,3-4,9-10H2,1-2H3
C-1311 is an imidazoacridinone analog. It is a next-generation investigational anticancer drug. It is an antitumor inhibitor of topoisomerase II and FMS-like tyrosine kinase 3 receptor. It was evaluated in phase I and II clinical trials for the treatment of various types of tumors. Mild treatment-related adverse events were thrombocytopenia, anemia, nausea, vomiting and diarrhea. Serious adverse event is neutropenia.
Originator
Approval Year
Doses
AEs
Sourcing
PubMed
Patents
Sample Use Guides
The initial dose was 480 mg/m2, 1 hr IV infusion on d 1, 8, and 15 of a 28 day cycle.
Route of Administration:
Intravenous
Acute treatments (3 h) of the a human tumour line (HeLa S3) revealed that cells exposed to C-1311 levels, which first induced persistent G2 arrest (0.5 ug/ml), subsequently died from this compartment, while doses exceeding these levels (1.0 ug/ml), paradoxically, did not cause the same extensive cell death.
ACTIVE MOIETY
![Structure of 5-Amino-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one](/img/0ddae645-3388-4bfa-b2af-cab89161541c.svg "Structure of 5-Amino-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one")
